sitagliptin/metformin hexal 50 mg / 850 mg tabletti, kalvopäällysteinen
hexal a/s - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja sitagliptiini
sitagliptin/metformin grindeks 50 mg / 1000 mg tabletti, kalvopäällysteinen
as grindeks (jsc grindeks) - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja sitagliptiini
sitagliptin/metformin grindeks 50 mg / 850 mg tabletti, kalvopäällysteinen
as grindeks (jsc grindeks) - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja sitagliptiini
sitagliptin/metformin glenmark 50 mg / 1000 mg tabletti, kalvopäällysteinen
glenmark arzneimittel gmbh - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja sitagliptiini
sitagliptin/metformin glenmark 50 mg / 850 mg tabletti, kalvopäällysteinen
glenmark arzneimittel gmbh - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja sitagliptiini
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
metformin actavis 500 mg tabletti, kalvopäällysteinen
actavis group ptc ehf - metformin hydrochloride - tabletti, kalvopäällysteinen - 500 mg - metformiini
metformin actavis 850 mg tabletti, kalvopäällysteinen
actavis group ptc ehf - metformin hydrochloride - tabletti, kalvopäällysteinen - 850 mg - metformiini
metformin stada 1000 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - metformin hydrochloride - tabletti, kalvopäällysteinen - 1000 mg - metformiini
metformin vitabalans 500 mg tabletti, kalvopäällysteinen
vitabalans oy - metformin hydrochloride - tabletti, kalvopäällysteinen - 500 mg - metformiini